CTXR: Riding the Market Waves of Growth and Decline in 2023

The stock price performance for the year has been a mixed bag, indicating either a pessimistic or optimistic outlook depending on how you look at it. Year to date metric has recorded a gain of 36.15%.However, over the last six months, we can see a weaker performance of 48.87%. Over the last 30 days, the price of CTXR has fallen by 34.06%. And in the last five days, it has surged by 30.68%.

Citius Pharmaceuticals Inc experienced a rather shaky stock market performance. The highest value in the past year was recorded at $1.71 on 04/17/23 and the lowest value was $0.60 on 02/08/24.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


52-week price history of CTXR Stock

Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Citius Pharmaceuticals Inc’s current trading price is -39.77% away from its 52-week high, while its distance from the 52-week low is 71.67%. The stock’s price range during this period has varied between$0.60 and $1.71. The Citius Pharmaceuticals Inc’s shares, which operate in the Healthcare, saw a trading volume of around 1.8 million for the day, a figure considerably higher than their average daily volume of 0.68 million over last three months.

Market Capitalization vs. Financial Performance: A Comparative Study

Citius Pharmaceuticals Inc (CTXR) has experienced a quarterly rise of 33.47% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 163.86M and boasts a workforce of 22 employees.

Combining Moving Average and Trading Volume Data for Better Market Insight

Based on Barchart.com data, the company’s moving average over the 100-day period was 0.7533, with a change in price of +0.2539. Similarly, Citius Pharmaceuticals Inc recorded 614,619 in trading volume during the last 100 days, posting a change of +32.71%.

CTXR’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look

The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for CTXR stands at 0.01. Similarly, the long-term debt-to-equity ratio is also 0.00.

CTXR Stock Stochastic Average

Citius Pharmaceuticals Inc’s raw stochastic average for the past 50 days is presently 91.49%, as of today. This marks a increase from the raw stochastic average of the last 20 days, which was 90.48%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 88.98% and 88.34%, respectively.

On Key

Related Posts